Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial With CLD-101 Virotherapy in Patients With Recurrent High-Grade Glioma
March 27, 2025
March 27, 2025
DUARTE, California, March 27 -- City of Hope issued the following news release:
* * *
Calidi Biotherapeutics and City of Hope provide update on a phase 1 clinical trial with CLD-101 virotherapy in patients with recurrent high-grade glioma
SAN DIEGO AND LOS ANGELES - Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, and City of Hope, . . .
* * *
Calidi Biotherapeutics and City of Hope provide update on a phase 1 clinical trial with CLD-101 virotherapy in patients with recurrent high-grade glioma
SAN DIEGO AND LOS ANGELES - Calidi Biotherapeutics, Inc. (NYSE American: CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, and City of Hope, . . .